To arrange a meeting with management, please contact Keely Zipp at or visit the BIO One-on-One Partnering webpage or 6 th Annual Digital Immuno-Oncology Innovation Forum webpage to schedule a meeting directly. Members of the management team will be available for virtual meetings throughout BIO Digital and the 6 th Annual Digital Immuno-Oncology Innovation Forum. Access to this conference is free for investors via the link: Hellsund will also be a member of the ‘Latest Trends in C&G Therapeutics II: Focusing on Cancer Vaccines, Neo Antigens & Other Modalities’ panel which will be broadcast live on Wednesday, at 11am ET. In addition, Cybrexa will present at the Sachs 6 th Annual Digital Immuno-Oncology Innovation Forum that is being held May 26-27, 2020. Hellsund will also be one of the senior leaders speaking at the BIO Digital panel ‘Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies’, which will be available on demand starting on June 8. The company presentation will be available on demand starting on June 8. He will also highlight the potential applications of alphalex™ to improve the therapeutic index of cancer therapeutics. Hellsund will present a corporate overview on the Company’s platform, pipeline, and lead candidate CBX-12 (alphalex™-exatecan), which is expected to enter the clinic in advanced solid tumors in early 2021. NEW HAVEN, Conn., (GLOBE NEWSWIRE) - Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, today announced Per Hellsund, President and Chief Executive Officer, will present at the 2020 BIO Digital Conference being held June 8-12, 2020.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |